טוען...
Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome
BACKGROUND: Rituximab (RTX) has recently been introduced as a second-line therapy for nephrotic syndrome in children. Studies show that RTX given during the nephrotic state may be less effective than treatment during a non-nephrotic state, possibly due to loss of RTX in the urine. CASE-DIAGNOSIS/TRE...
שמור ב:
| הוצא לאור ב: | Pediatr Nephrol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Berlin Heidelberg
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4483248/ https://ncbi.nlm.nih.gov/pubmed/26054711 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-015-3120-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|